Philips is recalling all sizes of its Tack Endovascular System after 20 patient injuries were reported. Interventional cardiologists are urged to stop using the device immediately. 

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

The American College of Cardiology and American Heart Association published the new guidelines with assistance from other leading U.S. medical societies. 

The ACC, AHA, HFSA, HRS and SCAI all worked together to try and make the new board a reality. Though their proposal has been denied, the groups say they are not done fighting. 

The acquisition helps Teleflex expand its interventional and vascular portfolios. Biotronik, meanwhile, is shifting its focus toward implantable devices and digital healthcare. 

Second-generation TAVR valves from Medtronic, Edwards Lifesciences and Boston Scientific are all associated with similar seven-year outcomes, according to a new retrospective study out of Italy. 

The paclitaxel-coated device, already approved in Europe and other parts of the world, will be tested on more than 1,200 patients for a new international trial. If the study is a success, Medtronic hopes to gain regulatory approval in the United States and Japan. 

Transfemoral TAVR is not always a viable option. In those instances, the two most effective alternatives are transcarotid access and transcaval access, according to a new SCAI expert consensus statement.